QT Imaging’s Breast Acoustic CT™ Scanner to be Offered at The Center for New Medicine to Advance Personalized Prevention and Detection of Breast Cancer
- None.
- None.
Insights
The partnership between QT Imaging Holdings, Inc. and the Center for New Medicine introduces the QT Imaging Breast Acoustic CT™ Scanner into a prominent integrative medical clinic, potentially signaling a shift in the medical imaging sector. This technology, being the only 3D imaging device of its kind with FDA clearance, represents a notable advancement in breast cancer screening, particularly for women with dense breast tissue. The availability of this device could disrupt the current standard of care, which often relies on mammography, by offering a non-invasive, radiation-free alternative that could lead to earlier and more accurate detection of breast cancer.
From a business perspective, the adoption of QT Imaging's technology by a leading medical center could serve as a pivotal reference case, potentially accelerating market penetration and acceptance of their device. The cost-effectiveness and improved patient experience touted by the device could drive demand, especially in the context of rising healthcare costs and increasing patient advocacy for less invasive diagnostic procedures. However, it's important to monitor the scalability of production and distribution to meet potential increases in demand, as well as the company's ability to maintain quality standards during expansion.
The strategic partnership and distribution agreement could have significant financial implications for QT Imaging Holdings, particularly if the technology gains traction within the women's health market. By providing a cost-effective and patient-friendly alternative to traditional breast imaging methods, QT Imaging may capture market share from existing mammography solutions. This could lead to increased revenue streams and potentially impact the company's stock valuation positively, assuming widespread adoption and favorable clinical outcomes.
Furthermore, the emphasis on a patient-centric approach aligns with broader healthcare trends towards personalized medicine. This alignment may enhance the company's brand reputation and could lead to strategic partnerships with other integrative medicine centers or healthcare providers. Investors should consider the potential for QT Imaging's technology to set a new standard in breast health imaging, which could have long-term implications for the company's growth trajectory and the broader medical device industry.
The regulatory aspect of the QT Imaging Breast Acoustic CT™ Scanner's FDA clearance is a critical factor in its market viability and potential impact on public health policy. The clearance not only validates the safety and efficacy of the device but also sets a precedent for future low-frequency soundwaves imaging systems. If this technology demonstrates a significant improvement in early cancer detection rates, it could influence healthcare policy, potentially leading to changes in recommended screening practices and insurance coverage.
It's also worth considering the broader implications for women's health initiatives and the potential for this technology to address disparities in breast cancer outcomes. If the device proves to be more effective for women with dense breasts—who are at a higher risk of breast cancer and often face challenges with traditional screening methods—it could become an essential tool in reducing mortality rates and improving health equity. However, the long-term impact will depend on QT Imaging's ability to navigate the complex healthcare reimbursement landscape and the ongoing collection of clinical data supporting the device's efficacy.
There is tremendous opportunity for new technology to advance women’s health, especially in breast cancer detection and treatment. QT Imaging Breast Acoustic CT™ Scanner is the only 3D imaging device to receive FDA clearance for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast. This breast scanning system offers women, especially those with dense breasts, a supplemental screening option to ensure their breast health over time. For providers, the technology is more affordable and yields better visualization of the internal structures of the breast without radiation, compression, or use of harmful contrast agents.
Dr. Leigh Erin Connealy is the Medical Director of Center for New Medicine and Cancer Center for Healing and is a prominent leader in the Integrative/Functional Medicine field. “The Center for New Medicine centers its services on an integrated and precise approach to medicine. The QT Imaging Breast scanning system provides our patients with an alternative, more accurate and less expensive choice to traditional modalities that ensure breast health,” stated Dr. Connealy.
“The QTI Breast Acoustic CT™ System presents significant advantages to a patient-centric approach,” said Dr. Raluca Dinu, Chief Executive Officer of QT Imaging Holdings. “Patients and providers should never have to choose between accuracy and experience. Our technology prioritizes the patient experience while delivering high-quality, high-resolution 3D images. Our goal is to improve health outcomes by expanding access to superior medical imaging at lower costs to providers and patients.”
About QT Imaging
QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.
About Center for New Medicine
The Center for New Medicine focuses on a precise and personalized approach to patient care that includes prevention, early detection of cancer, internal medicine, auto-immune disease, natural hormone replacement, chronic issues, and even aesthetics. Dr. Connealy's clinics focus on treating “the patient with the disease and not the disease of the patient, while determining the origin of the illness." Center for New Medicine contains some of the world’s most technologically advanced medical equipment, devices normally only found at select university research hospitals. Our prescriptions routinely feature customized dietary and lifestyle recommendations, natural nutritional supplements and other complementary therapies that produce lifelong benefits. For more information on QT Imaging Holdings, Inc., please visit the company’s website at https://www.cfnmedicine.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the strategic partnership between QT Imaging Holdings and our previously disclosed distribution partner, the QTI Breast Acoustic CTTM System, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: the ability of the parties to sell and deploy the QTI Breast Acoustic CTTM System, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging’s (and its predecessor, GigCapital5, Inc.) filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411289276/en/
For media inquiries, please contact:
Susan Schaffler
Head of Communications
Susan.Schaffler@qtimaging.com
Stas Budagov
Chief Financial Officer
Stas.Budagov@qtimaging.com
Source: QT Imaging Holdings, Inc.
FAQ
What is the name of the medical device company mentioned in the press release?
What is the ticker symbol for QT Imaging Holdings, Inc.?
What innovative body imaging systems does QT Imaging Holdings, Inc. specialize in?
What is the name of the strategic business and distribution partner mentioned in the press release?
What type of medical clinic is the Center for New Medicine?
What is the primary focus of the Center for New Medicine's services?
What FDA clearance did the QT Imaging Breast Acoustic CT™ Scanner receive?
What advantages does the QT Imaging Breast Acoustic CT™ Scanner offer for women with dense breasts?
Who is the Medical Director of the Center for New Medicine and Cancer Center for Healing?
What is the goal of QT Imaging Holdings, Inc. with the QTI Breast Acoustic CT™ System?
